Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

TG Therapeutics highlights potential of ublituximab for new indication

Aug. 28, 2012

Updated results from EMILIA study of trastuzumab emtansine

Aug. 27, 2012

Northwest Bio gains MHRA clearance for DCVax-L trial

Aug. 24, 2012

NICE publishes draft guidance on denosumab

Aug. 20, 2012

Lykera Biomed reports novel S100-P-directed antibodies

Aug. 20, 2012

New candidate immunotherapies divulged by UCB

Aug. 17, 2012

Biovest holds end-of-phase III meeting for BiovaxID

Aug. 16, 2012

Phase III study of OCV-C01 advances

Aug. 13, 2012

New ROR1-binding antibodies designed in California

Aug. 9, 2012

NIH designs recombinant oncolytic immunotoxins that may be given at high doses

Aug. 9, 2012

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...